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| INTRODUC TI ON
Huntington's disease (HD) is a neurodegenerative ailment which results from a trinucleotide CAG repeat expansion in the chromosomes of affected individuals and is distinguished for movement, psychiatric, and cognitive disturbances. 1 As other neurodegenerative disorders, HD exhibits progressive alteration in neuronal function that leads to cell death of medium spiny neurons (MSNs) in the striatum. The causes of neuronal degeneration are not completely understood, but alterations in mitochondrial function, oxidative stress, and changes in trophic support contribute to HD pathogenesis. 2 In particular, brain-derived neurotrophic factor (BDNF) action on MSNs is well known, and reduced level of BDNF and its TrkB receptor have been documented in HD, 3 but it is not completely understood if other neurotrophins exert neuroprotective effect on MSNs and could be tested for therapeutic treatment in HD.
Neurotrophin-3 (NT-3), a trophic factor from the neurotrophin family, is widely expressed in the nervous system. Similar to other neurotrophins, the physiological actions of NT-3 are mediated by the activation of two membrane receptors: the low-affinity receptor p75 
Summary
Aims: Neurotrophin-3 (NT-3) is expressed in the mouse striatum; however, it is not clear the NT-3 role in striatal physiology. The expression levels of mRNAs and immune localization of the NT-3 protein and its receptor TrkC are altered in the striatum following damage induced by an in vivo treatment with 3-nitropropionic acid (3-NP), a mitochondrial toxin used to mimic the histopathological hallmarks of Huntington's disease (HD). The aim of this study was to evaluate the role of NT-3 on corticostriatal synaptic transmission and its plasticity in both the control and damaged striatum.
Methods: Corticostriatal population spikes were electrophysiologically recorded and striatal synaptic plasticity was induced by high-frequency stimulation. Further, the phosphorylation status of Trk receptors was tested under conditions that imitated electrophysiological experiments.
Results: NT-3 modulates both synaptic transmission and plasticity in the striatum; nonetheless, synaptic plasticity was modified by the 3-NP treatment, where instead of producing striatal long-term depression (LTD), long-term potentiation (LTP) was obtained. Moreover, the administration of NT-3 in the recording bath restored the plasticity observed under control conditions (LTD) in this model of striatal degeneration.
Conclusion: NT-3 modulates corticostriatal transmission through TrkB stimulation
and restores striatal LTD by signaling through its TrkC receptor.
K E Y W O R D S
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Each neurotrophin binds to one specific subtype of Trk; however, NT-3 activates the TrkC receptor and binds with less affinity to TrkB and TrkA. [4] [5] [6] Through the activation of its receptors, NT-3 reduces cellular damage, improves neuronal regeneration in different models of lesions or neurodegeneration, and participates in synaptic reorganization, synapse formation, and neuronal plasticity. [7] [8] [9] [10] [11] [12] [13] Although NT-3 protects striatal cells from excitotoxicity, 14 the trophic and modulatory effects of NT-3 on striatal physiology have been poorly explored. As shown in our previous study, NT-3 is expressed in the striatum 15 and modulates corticostriatal synaptic activity; furthermore, this modulatory effect is reduced in the presence of striatal neurodegeneration induced by 3-nitropropionic (3-NP) in vivo. Modifications in the modulatory effects of NT-3 are accompanied by a reduction in NT-3 levels in the striatum. 16 3-NP is a mitochondrial complex II inhibitor, 17, 18 which has been widely used as a pharmacological model of HD. As a result of impairing the mitochondrial respiratory chain, 3-NP produces abnormal movements, cognitive deficits, and striatal degeneration that mimics the histopathology observed in the postmortem tissue from patients afflicted with this illness.
19-23
Our former observations showed that NT-3 plays an important role in striatal physiology; however, the mechanisms involved remain to be elucidated. Then, this study evaluates the modulatory effect of NT-3 on corticostriatal synaptic plasticity in the 3-NP-treated animal model of HD and describes the Trk receptors involved in its effects.
Based on our data, we conclude that NT-3 modulates corticostriatal synaptic transmission and corticostriatal LTD. 
| 3-NPtreatment
Mice were randomly assigned to the control and 3-NP-treated groups. Mice in the 3-NP group received one daily intraperitoneal (i.p.) injection of 3-NP (15 mg/Kg, dissolved in 0.1 mol L −1 phosphate buffer (PB), pH 7.4) for 5 days, to produce early stages of HD. 22, 23 Mice in the control group received an equivalent volume of the vehicle for 3-NP (PB) according to mouse weight. Electrophysiological recordings and Western blot experiments were performed 2 days after the administration of the last 3-NP treatment. 
| Slicepreparation

| Recordingsofextracellularsynaptic populationspikes
Slices were immersed in a recording chamber and continually perfused with an artificial cerebrospinal saline (in mmol L −1 : 125 NaCl, 
| Westernblot
Striatal slices from the control group and 3-NP-treated mice were treated with NT-3 (50 ng/mL), NT-3 (50 ng/mL) + high K + (50 mmol The amplitude of the spike in response to the first stimulation (S1) increased 57% ± 6% compared to the control condition (t 16 = −38.31; P < 0.001) in the control tissue, whereas in slices from animals treated with 3-NP, the increase in the amplitude of S1 was 30% ± 5.7% Images were acquired (Gel Documentation System, BioSens SC 645, Shanghai Bio-Tech Co., Ltd.) and densitometrically analyzed using ImageJ software (NIH).
| Drugs
All reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless stated otherwise.
F I G U R E 2 Corticostriatal LTD is modulated by NT-3. A, Time course of the population spike amplitude in control and NT-3-treated slices after HFS (arrow). Note that LTD is obtained under both conditions but to different extents. Control slices without NT-3 (57.9% ± 3.7%, t 17 = 73.09; P < 0.001) vs slices treated with NT-3 (28.8% ± 2.4%, t 29 = 65.23; P < 0.001). B, Representative traces of population spikes in control slices before and after HFS. C, Representative traces of population spikes in control slices in the presence of NT-3 before and after HFS. D, PPR (S2/S1) in untreated control slices and in the presence of NT-3. Note that presynaptic mechanisms are involved in the LTD generated in control slices; however, a postsynaptic mechanism mediates the effects of NT-3 on LTD (n = 6; Mean ± SE)
| Statisticalanalysis
All data were analyzed with Sigma Plot 12 software (Softek, SPSS Inc., San José, CA) and expressed as Means ± SEM. One-way ANOVA with a post hoc test or Student's t test (paired or unpaired, depending on the experiment) was used for comparisons between groups.
Experiments without normal distribution data were analyzed with nonparametrical test. Statistical significance was set to P < 0.05.
| RE SULTS
| ModulatoryeffectsofNT-3oncorticostriatal transmission
In the first set of experiments, the effects of NT-3 on corticostriatal synaptic responses were evaluated. NT-3 (50 ng/mL) significantly increased the synaptic responses of both experimental groups. A greater increase in the mean amplitude was observed in the control group than in the 3-NP group, but this difference was not significant. However, the distribution of the data increased when NT-3 was administered to the control group, but not the slices from the 3-NP-treated group ( Figure 1A) . Figure 1B , C shows representative recording traces. Modulatory effects of NT-3 on the control and 3-NP groups seemed to rely on postsynaptic mechanisms, as the analysis of PPR did not show differences ( Figure 1D ).
| ModulatoryeffectsofNT-3onlong-term corticostriatalsynapticplasticity
We first evaluated plasticity in control tissues to evaluate the effect on NT-3 on corticostriatal plasticity. The HFS protocol in the corticostriatal pathway produced LTD in the control group; the HFS also F I G U R E 3 NT-3 reestablished corticostriatal LTD in an animal model of HD. A, Time course of the population spike amplitude in slices from 3-NP-treated mice after HFS. 3-NP-treated slices exhibited an increase in the spike amplitude after HFS (38.8% ± 3.5%, t 19 = −48.7, P < 0.001); however, in the presence of NT-3, 3-NP-treated slices exhibited a decrease in amplitude after HFS, (36.3% ± 4.1%, t 19 = 38.81; P < 0.001). B, Representative traces of population spikes in slices from 3-NP-treated mice before and after HFS (arrow). HFS triggers LTP in 3-NP-treated slices. C, Representative traces of population spikes in slices from 3-NP-treated mice before and after HFS and in the presence of NT-3. Note that NT-3 reestablished LTD to the levels observed in control tissues (Fig. 2) . D, PPR (S2/S1) in 3-NP slices and 3-NP slices + NT-3. There were no significant differences in both experimental conditions. Note that postsynaptic mechanism mediates the effects of NT-3 on the reestablishment of LTD in slices from 3-NP-treated mice (n = 6; Mean ± SE) produced stable LTD in the presence of NT-3 ( Figure 2A ). Although NT-3 produced a lower decrease in the amplitude of LTD, differences between groups were not observed ( Figure 2B, C) . In control slices, LTD expression was mediated by a presynaptic mechanism;
however, NT-3 modulation of LTD induction was mediated by a postsynaptic mechanism ( Figure 2D ).
| NT-3restorescorticostriatalsynapticplasticity inthe3-NP-treatedanimalmodelofHD
We next evaluated synaptic plasticity in slices from 3-NP-treated mice. HFS produced LTP in slices from the 3-NP-treated mice.
However, if NT-3 was present in slices from 3-NP-treated mice, HFS induced LTD. In other words, the presence of NT-3 reestablished LTD ( Figure 3A , B, C). Both, the LTP and LTD generated in the corticostriatal synapses of 3-NP-treated tissues was mediated by postsynaptic mechanisms ( Figure 3D ).
| ThemodulatoryeffectsofNT-3on corticostriatalsynapsesaremediatedbyTrkB receptors,andeffectsonLTDarenotmediatedby TrkBreceptorsactivation
NT-3 is known to bind TrkC and with less affinity to TrkB. Therefore, the TrkB antagonist CTX-B was used to discern which receptor was involved in the NT-3-mediated modulation of corticostriatal synapses. First, the effect of CTX-B on healthy slices was evaluated; modulatory effect of NT-3 was prevented by the CTX-B; however, CTX-B did not affect LTD produced by HFS + NT-3 ( Figure 4A , B).
PPR analysis of NT-3 effect in the presence of CTX-B on modulation and striatal plasticity did not show statistical differences ( Figure 4C , D, respectively).
Next, we evaluated whether the inhibition of TrkB in slices from 3-NP-treated mice changed NT-3 effects on synaptic modulation and on striatal LTD. In the presence of CTX-B, NT-3 did not produce any modulatory effect on corticostriatal synapses ( Figure 5A , B) and changes were not observed in the PPR analysis ( Figure 5C ).
The next series of experiments were conducted in the presence of CTX-B and NT-3 and after 10-20 minutes of stable recording, the HFS protocol was administered. Under this condition, a strong LTD was obtained ( Figure 5D , E). According to the PPR analysis, a postsynaptic mechanism mediated this effect of NT-3 on striatal LTD ( Figure 5F ). Based on the results from these experiments, we concluded that TrkB was not involved in NT-3-mediated modulation of striatal LTD. Therefore, the modulatory effects of NT-3 on corticostriatal plasticity were mediated mainly by the activation of postsynaptic TrkC receptors. 
| PhosphorylationofTyr816-TrkBand
| CON CLUS ION
Based on our results, NT-3 modulates the glutamatergic synaptic responses of the corticostriatal pathway in the healthy and damaged striatum, consistent with our previous report. 16 NT-3 also modulates the long-term plasticity of corticostriatal transmission through postsynaptic mechanisms. HFS produced LTP in response to 3-NP-induced striatal degeneration. Nevertheless, the presence of NT-3 in the slices of 3-NP-treated mice restored long-term depression in corticostriatal synapses. The activated receptor involved in modulating corticostriatal transmission was TrkB, whereas TrkC seemed to be involved in restoring corticostriatal LTD.
A 3-NP treatment has been shown to trigger LTP after HFS, 25, 26 and mitochondrial inhibition affects the membrane potential and increases the sensitivity of NMDA and AMPA receptors to glutamate, favoring the activity of PKA, which has been linked to the generation of striatal LTP. 27, 28 Nevertheless, this LTP is considered pathological; meanwhile, LTD is the physiological form of plasticity most frequently observed in the striatum. Moreover, corticostriatal LTD involves endocannabinoid synthesis, which act as retrograde messengers at the corticostriatal synapses, activating CB1 receptors at the presynaptic neuron which, in turn, reduces neurotransmitter release and maintains LTD expression. 29 However, for LTD induction, different postsynaptic mechanisms are involved. 30 This study demonstrates that the mechanism by which NT-3 modulates corticostriatal LTD in healthy tissue and restores LTD of damaged Future experiments will test this hypothesis.
The modulatory effect of NT-3 on corticostriatal synapses was mediated by the activation of TrkB receptors; the use of the TrkB blocker prevented the NT-3-mediated modulation. However, the effect of NT-3 on striatal plasticity in both healthy and slices from 3-NP-treated mice was not inhibited by CTX-B. NT-3 has been reported to use different mechanism to modulate acute and long-term plasticity. 8, 32 Western blots showed that TrkC phosphorylation was increased by NT-3 in the presence of high K + which was used to mimic HFS, indicating that NT-3 restored LTD in the 3-NP model by activating preferentially TrkC receptors. Although NT-3 also activates TrkA, it is unlikely that NT-3 effects on LTD are mediated by TrkA stimulation, as we have shown that NGF did not affect corticostriatal transmission, 16 and we did not find changes in the phosphorylation state of TrkA receptors in our experimental conditions that could suggest its participation in the NT-3 effects in the present study.
The effects of NT-3 on neuronal plasticity in other cerebral areas 11, [33] [34] [35] or at the neuromuscular junction 36, 37 have been described. In the striatum, the research on neurotrophins has focused on describing the trophic effects of brain-derived neurotrophic factor (BDNF) on striatal MSNs, because defective huntingtin generated by the HD mutation impedes BDNF transcription. 3 However, as stated above, NT-3 also activates TrkB receptors, 38 and some of the actions ascribed to BDNF may be mediated by NT-3. As shown in the present study, the modulatory effects of NT-3 on corticostriatal synapses are mediated by TrkB activation; however, LTD was modulated and reestablished by the activation of TrkC. In previous studies, we documented a decrease in the NT-3 levels in response to 3-NP-induced striatal degeneration. 39 If the 3-NP treatment reduced NT-3 levels, HFS produced LTP; however, the exogenous addition of NT-3 to the recording bath reestablished the LTD by activating TrkC receptors, the levels of which are known to be increased in this model of striatal degeneration.
39
Our animal model of neurodegeneration mimics the early histopathological and neurophysiological events of HD, such as dysregulation of glutamatergic cortical inputs to the striatum along with an increase in the postsynaptic excitatory currents. 40, 41 These changes partially explain how HFS induces LTP in our model of HD.
Neuronal damage, as evidenced by changes in synaptic activity and the number of dendritic spines in the MSNs, also produces a synaptic disconnection. 16 The progressive reduction in corticostriatal synaptic activity affects BDNF release and subsequently enhances cellular dysfunction and degeneration of the MSNs. 41 Similar to patients with HD and the transgenic mouse model, BDNF levels are also reduced in the 3-NP-induced neurodegeneration model. 16, 39 The decreased BDNF levels will fail to trigger neuronal survival and neuronal protection of MSNs. However, if NT-3 is present in the striatum, it would stimulate TrkB and TrkC receptors and trigger signaling pathways related to neuroprotective mechanisms as well modulatory actions. 42 Therefore, experimental strategies that increase NT-3 levels in the degenerated striatum would be a good candidate to overcome with neuronal death.
To our knowledge, the present study is the first one to report that NT-3 restores striatal LTD in a degeneration model of HD. Also, our results show that NT-3 actively participates in striatal physiology, and as synaptic plasticity is important to maintain striatal function, we are currently investigating which signaling pathway(s) is (are) involved in these modulatory effects.
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